InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations.
On April 26, 2017, InspireMD, Inc. (the Company) announced that
its Board of Directors has established June 29, 2017, as the date
for the Companys 2017 Annual Meeting of Stockholders (the Annual
Meeting) and set May 8, 2017 as the record date for the Annual
Meeting. Due to the fact that the date of the Annual Meeting has
been changed by more than 30 days from the anniversary date of
the 2016 Annual Meeting of Stockholders, the Company is providing
the due date for submission of any qualified stockholder proposal
or qualified stockholder nominations.
In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the
Securities Exchange Act of 1934, as amended (the Exchange Act),
and the Companys amended and restated bylaws, the deadline for
receipt of stockholder proposals or nominations for inclusion in
the Companys proxy statement for the Annual Meeting to Rule 14a-8
will be no later than 5:00 p.m., Eastern Time, May 8, 2017.
Stockholder proposals must comply with all of the applicable
requirements set forth in the rules and regulations of the
Securities and Exchange Commission, including Rule 14a-8 under
the Exchange Act and the Companys amended and restated bylaws.
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session up +0.025 at 0.690 with 97,557 shares trading hands.
